• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Recognized Consensus Standards

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

New Search Back To Search Results
Part B: Supplementary Information Sheet (SIS)
FR Recognition List Number 052 Date of Entry 07/15/2019 
FR Recognition Number 7-289
Standard
CLSI MM17 2nd Edition
Verification and Validation of Multiplex Nucleic Acid Assays
Scope/Abstract
This document discusses analytical validation and verification of qualitative multiplex nucleic acid assays. Topics covered include sample preparation, a general discussion of multiplex methods and technologies, reference and quality control materials, data analysis, and results reporting. Clinical validity and utility are briefly reviewed. Because of the variety and breadth of multiplex testing, specific protocols for validation and verification are not included. However, detailed recommendations for appropriate analytical validation and verification, based on the most current guidance documents, are provided.
Extent of Recognition
Partial recognition. The following part(s) of the standard is (are) not recognized:
Chapter 2.4 Validation and Verification Protocols
Chapter 2.5 Analytical Validation of a Laboratory-Developed Test
Chapter 2.6 Analytical Validation of a Modified In Vitro Diagnostic Assay
Chapter 2.7 Verification of an In Vitro Diagnostic Assay
Rationale for Recognition
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies.

Standard is recognized on a scientific basis: Device performance.

Chapter 2.4 does not satisfy the requirement for analytical performance characteristics under 21 CFR 809.10(b)(12) Specific Performance Characteristics and 21 CFR 807.87 because it describes requirements for validation and verification in clinical laboratories and not for submitters of premarket submissions to establish IVD performance for marketing purposes.

Chapter 2.5, Chapter 2.6 and Chapter 2.7 does not satisfy the requirement for analytical performance characteristics under 21 CFR 809.10(b)(12) Specific Performance Characteristics and 21 CFR 807.87 because it was developed for clinical laboratories and not for submitters of premarket submissions to establish IVD performance for marketing purposes.
Public Law, CFR Citation(s) and Procode(s)*
21 CFR 809.10(b)(12)
21 CFR 807.87
Relevant FDA Guidance and/or Supportive Publications*
Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses Guidance for Industry and Food and Drug Administration Staff, Issued September 2017.
FDA Technical Contacts
 Sharon (Xueying) Liang
  FDA/OMPT/CDRH/OIR/DMGP/MGB/
  301-796-9601
  sharon.liang@fda.hhs.gov
 Himani Bisht
  FDA/OC/CDRH/OPEQ/OIDRH/DMD/VIR1/
  301-796-6189
  HIMANI.BISHT@FDA.HHS.GOV
Standards Development Organization
CLSI Clinical Laboratory Standards Institute https://clsi.org/
FDA Specialty Task Group (STG)
InVitro Diagnostics
*These are provided as examples and others may be applicable.
-
-